Clinical Trials in China / NCT07584213
Active, not recruiting
Observational
The Association Between Blood Routine Parameters and Breast Cancer Prognosis
NCT07584213 · tracked via the Priya Life Science China tracker
Condition(s) studied
Breast Cancer Invasive
Investigational drug(s) / intervention(s)
blood routine test
blood routine test: blood routine test at baseline
Study summary
This is a real-world multicentre study to investigate the association between blood routine parameters combined with clinicopathological characteristics and breast cancer prognosis.
Eligibility
Inclusion Criteria:
* Aged 18 years or older
* Pathologically confirmed invasive primary breast cancer
Exclusion Criteria:
* De novo stage IV breast cancer
Primary outcome measure(s)
- Disease-free survival — From the date of radical surgery until time of event up to 3 years
Disease-free survival time is defined as the time from the date of radical surgery until the date of the first occurrence of local/regional relapse, distant recurrence, contralateral breast cancer, second malignancy and death from any cause.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiaotong University | Shanghai | China |
More Wenjin Yin trials in China
The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis
Active, not recruiting
Other trials for the same condition
The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis
Active, not recruiting
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07584213 on ClinicalTrials.gov ↗ ← All trials in China